---
title: "Cytophage Technologies Appoints James Kinley as Chief Financial Officer"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/273086174.md"
description: "Cytophage Technologies Ltd. has appointed James Kinley as its new Chief Financial Officer, succeeding Julius Kalcevich. Kinley, who has experience in the biotech industry, will serve as a fractional CFO. Kalcevich will assist during the transition and remain available as an independent consultant."
datetime: "2026-01-20T12:50:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273086174.md)
  - [en](https://longbridge.com/en/news/273086174.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273086174.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/273086174.md) | [繁體中文](https://longbridge.com/zh-HK/news/273086174.md)


# Cytophage Technologies Appoints James Kinley as Chief Financial Officer

Cytophage Technologies Ltd. has appointed James Kinley as its new Chief Financial Officer, replacing Julius Kalcevich. Kinley brings experience from the biotech industry and will serve as a fractional CFO. Kalcevich will assist with the transition and remain available as an independent consultant. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytophage Technologies Ltd. published the original content used to generate this news brief via TheNewswire (Ref. ID: 1BOxF7ngq) on January 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [Cyclerion Therapeutics, Inc. (CYCN.US)](https://longbridge.com/en/quote/CYCN.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [Direxion Daily S&P Biotech Bear 3X ETF (LABD.US)](https://longbridge.com/en/quote/LABD.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [What is HC Wainwright's Estimate for KROS FY2030 Earnings?](https://longbridge.com/en/news/278112283.md)
- [Ocugen 10-K: Revenue $4.4M, Net Loss $67.8M](https://longbridge.com/en/news/277812097.md)
- [Senseonics Holdings: Q4 Earnings Insights](https://longbridge.com/en/news/277517921.md)
- [bioAffinity Showcases Sputum-Based Platform for Personalized Asthma Care](https://longbridge.com/en/news/277701323.md)
- [Bluejay 10-K: Net loss $6.85M, operating loss $6.95M; cash through Q3 2026](https://longbridge.com/en/news/278166044.md)